GiveBetter x SF

Homeless Prenatal Program

Conditional whole-organization value of a $100,000 unrestricted gift

Research time: ~17 min on GPT-5.6 Sol Medium
  • Research — organization and evidence review.
  • Modeling — cost-effectiveness analysis.
  • Historical estimate for research done before time tracking.

Published: September 8, 2026.

Donate

Summary

What do they do? Current official pages describe psychotherapy and maternal wellness. A distinct perinatal depression protocol, new funded cohort and longitudinal treatment outcomes remain unverified. More

Why this approach interests us

  • HPP provides psychotherapy alongside pregnancy and family support. Flexible support could help depressed pregnant or postpartum clients receive effective care.

Our main reservations

  • Current additional caseload, treatment fidelity, financing replacement and preference-valued health gains are unknown. Existing covered clinical care and publicly funded HPP services form the baseline.

What do you get for your dollar?

Conditional central donor cost is $27.61 million per 10 SF QALYs. The joint favorable case is $802,836 donor and $1,036,997 gross resources. This quantifies one plausible maternal-treatment component while retaining every dollar of the general gift. Inspect formulas, inputs and sources.

central donor cost / 10 qalys
$27.61M SF / $26.77M Bay / $26.23M US — Same $100,000 gift: 0.036215 SF, 0.037359 Bay and 0.038121 US QALYs. Nested health is never additive.
whole-gift boundary
$100,000 once — 15% hypothetical maternal-depression allocation centrally. Remaining portfolio health is unquantified and all cost retained.
recipient
HPP · EIN 94-3146280 — Provider's giving page identifies the entity and general donation route.
central gross resource envelope
$103,000 — Adds unpriced outside clinical/noncash resources on nominal offers. Not net induced societal spending.

1. What do they do?

Current official pages describe psychotherapy and maternal wellness. A distinct perinatal depression protocol, new funded cohort and longitudinal treatment outcomes remain unverified.

Allocate the whole organization gift

A hypothetical share supports complete treatment offers; other spending remains in the numerator.

Add care beyond the public baseline

Financial additionality removes replaced financing; net clinical days compare with actual available care.

Count additional healthier days

Signed depression-free days already account for engagement, recovery, recurrence and alternative care.

Value finite maternal health

Apply an explicit utility prior over 548 days and discount once. No maternal or child lifetime health is added.

Scope of this review. No contacts-to-lives-saved conversion. Deduplicate maternal health across HPP, UCSF/ZSFG, RAMS and public contractors.

2. Monitoring and information sharing

HPP clients; maternal subset unmeasured

Official program disclosures. Bilingual onsite and virtual psychotherapy is described.

Our assessment. No verified named perinatal protocol or additional seat commitment.

Depressed Medicaid pregnant adults in Seattle–King County

MOMCare randomized multi-component care. Depression severity improved versus intensive maternity support.

Our assessment. Case mix, intervention fidelity and actual SF usual care differ; no wholesale trial transfer.

Especially comorbid PTSD subgroup

MOMCare economic analysis. 68 additional depression-free days over 18 months in that subgroup.

Our assessment. Primary indexed result; full-page fetch failed. Utility conversion and HPP marginal costs remain assumptions.

Whole HPP organization

Official entity disclosure and consolidated audit. EIN verified against provider giving page; current audit inspected.

Our assessment. Historical financial scale does not measure marginal maternal health.

3. Qualitative assessment

HPP provides psychotherapy alongside pregnancy and family support. Flexible support could help depressed pregnant or postpartum clients receive effective care.

Key reservations

  • The utility conversion is assumption-driven; net symptom-defined days are not direct preference-valued health.
  • Actual marginal allocation, new caseload, funding replacement and course quality remain unverified.
  • Favorable external subgroup efficacy may not transfer to the current HPP maternal population or ordinary psychotherapy.
  • Unmodeled housing, violence support, child health and employment may add value; retaining cost does not assert those benefits are absent.
  • Whole portfolio and partner patient-time must be deduplicated before adding estimates.

Benefits not included in our estimate

  • Maternal deaths or suicide prevented
  • Child survival and lifetime development
  • Housing stability and violence-related health beyond counted days
  • Employment, income, food and broader welfare
  • Health after the observation window and downstream savings

4. What do you get for your dollar?

A small finite maternal health stream against the whole gift

Central six nominal offers become 2.4 incremental offers, each with 30 added depression-free days and an assumed .2 utility contrast. Symptom-derived days are not direct QALY observations.

A better life is our comparison unit of 10 additional quality-adjusted life years (QALYs), potentially spread across people. These are uncertain estimates, not measured returns or verified donation offers.

How we calculate the estimate

Whole-gift maternal treatment bridge: Offers = gift × maternal allocation / complete cash per offer. QALYs = offers × financial additionality × (net depression-free days / 365 × utility × average daily discount − shared harm) − independent harm.
6 × .4 × (30/365 × .2 × .966268) = .038121 US QALYs; × .95 = .036215 SF QALYs. $100,000 × 10 / .036215 = $27,612,713 per 10 SF QALYs.

Model inputs and assumptions
Maternal-depression share / cash per offer
15% / $2,500 (range: 3–35% / $1,200–$5,000). Includes assessment failures, failed recruitment, therapy, supervision, access supports and allocated organizational overhead. No second overhead factor. Analyst judgment.
Financial additionality
40% (range: 10–80%; zero replacement-only case). New treatment opportunities instead of replaced public funds or other donors. Not the same as clinical benefit versus available care. Unmeasured local prior.
Signed net depression-free days
+30 days per offered eligible client (range: +3 to +68; −15 and zero diagnostics). Across 548 days versus actual care; includes completion, spontaneous recovery, recurrence and later treatment. MOMCare's positive PTSD subgroup is a favorable reference, not HPP efficacy. External evidence; local transfer judgment.
Utility contrast for a depression-free day
0.20 (range: 0.10–0.30; zero bridge case). Converts net days to QALYs. Symptom scores, remission and dollar valuations of a day are not themselves preference utility. Explicit assumption; no direct HPP utility data.
Finite observation / discount / gift delay
548 days / 3.5% / .25 years (range: 0–.5-year delay). Uniform allocation of signed net days; daily midpoint discount once. No post-window health. Changing window with fixed net days changes timing only. Evidence-window and timing assumptions.
Outside resources per nominal offer
$500 (range: $500–$1,000; donor-pays diagnostic). Outside complete cash treatment cost; hypothetical psychiatric/medication/noncash inputs. Envelope precedes financing replacement and is not net social cost. Unpriced judgment.
Bay / SF residence shares
98% / 95% (range: 90–100% / 80–98%). All health US; SF inside Bay. Location of a clinic does not establish residence; same partition for harms. Unmeasured residence priors.
Shared / independent present-valued loss
0 / 0 (range: .02 QALY per incremental offer / .1 US QALY at zero activity). Both harm inputs are already gift-date present-value QALY losses and receive no additional discount. Shared harm scales with new activity; independent loss persists without a new offer. Exclude losses already in net depression-free days. Diagnostic, not observed HPP harm.

Same $100,000 unrestricted gift in every scenario

  • central: SF donor: $27,612,713/10 QALYs. US/Bay/SF QALYs: 0.038121266 / 0.037358841 / 0.036215203. US/Bay donor prices: $26,232,077 / $26,767,426 per 10 QALYs. Gross envelope $103,000; US/Bay/SF resource prices: $27,019,040 / $27,570,449 / $28,441,094 per 10 QALYs.
  • favorable joint: SF donor: $802,836/10 QALYs. US/Bay/SF QALYs: 1.2710038 / 1.2710038 / 1.2455838. US/Bay donor prices: $786,780 / $786,780 per 10 QALYs. Gross envelope $129,167; US/Bay/SF resource prices: $1,016,257 / $1,016,257 / $1,036,997 per 10 QALYs.
  • pessimistic positive: SF donor: $26,458,655,475/10 QALYs. US/Bay/SF QALYs: 0.000047243519 / 0.000042519167 / 0.000037794815. US/Bay donor prices: $21,166,924,380 / $23,518,804,867 per 10 QALYs. Gross envelope $100,300; US/Bay/SF resource prices: $21,230,425,153 / $23,589,361,282 / $26,538,031,442 per 10 QALYs.
  • negative clinical effect: SF donor: No finite positive ratio/10 QALYs. US/Bay/SF QALYs: -0.019060633 / -0.018679420 / -0.018107601. US/Bay donor prices: No finite positive ratio / No finite positive ratio per 10 QALYs. Gross envelope $103,000; US/Bay/SF resource prices: No finite positive ratio / No finite positive ratio / No finite positive ratio per 10 QALYs.
  • no allocation: SF donor: No finite positive ratio/10 QALYs. US/Bay/SF QALYs: 0.0000000 / 0.0000000 / 0.0000000. US/Bay donor prices: No finite positive ratio / No finite positive ratio per 10 QALYs. Gross envelope $100,000; US/Bay/SF resource prices: No finite positive ratio / No finite positive ratio / No finite positive ratio per 10 QALYs.
  • replacement only: SF donor: No finite positive ratio/10 QALYs. US/Bay/SF QALYs: 0.0000000 / 0.0000000 / 0.0000000. US/Bay donor prices: No finite positive ratio / No finite positive ratio per 10 QALYs. Gross envelope $103,000; US/Bay/SF resource prices: No finite positive ratio / No finite positive ratio / No finite positive ratio per 10 QALYs.
  • no clinical difference: SF donor: No finite positive ratio/10 QALYs. US/Bay/SF QALYs: 0.0000000 / 0.0000000 / 0.0000000. US/Bay donor prices: No finite positive ratio / No finite positive ratio per 10 QALYs. Gross envelope $103,000; US/Bay/SF resource prices: No finite positive ratio / No finite positive ratio / No finite positive ratio per 10 QALYs.
  • rapid counterfactual recovery: SF donor: $414,190,695/10 QALYs. US/Bay/SF QALYs: 0.0025414177 / 0.0024905894 / 0.0024143469. US/Bay donor prices: $393,481,160 / $401,511,388 per 10 QALYs. Gross envelope $103,000; US/Bay/SF resource prices: $405,285,595 / $413,556,729 / $426,616,415 per 10 QALYs.
  • independent harm zero activity: SF donor: No finite positive ratio/10 QALYs. US/Bay/SF QALYs: -0.10000000 / -0.098000000 / -0.095000000. US/Bay donor prices: No finite positive ratio / No finite positive ratio per 10 QALYs. Gross envelope $103,000; US/Bay/SF resource prices: No finite positive ratio / No finite positive ratio / No finite positive ratio per 10 QALYs.
  • shared harm: SF donor: No finite positive ratio/10 QALYs. US/Bay/SF QALYs: -0.0098787339 / -0.0096811592 / -0.0093847972. US/Bay donor prices: No finite positive ratio / No finite positive ratio per 10 QALYs. Gross envelope $103,000; US/Bay/SF resource prices: No finite positive ratio / No finite positive ratio / No finite positive ratio per 10 QALYs.
  • donor covers outside care: SF donor: $33,135,256/10 QALYs. US/Bay/SF QALYs: 0.031767722 / 0.031132367 / 0.030179336. US/Bay donor prices: $31,478,493 / $32,120,911 per 10 QALYs. Gross envelope $100,000; US/Bay/SF resource prices: $31,478,493 / $32,120,911 / $33,135,256 per 10 QALYs.
  • no utility bridge: SF donor: No finite positive ratio/10 QALYs. US/Bay/SF QALYs: 0.0000000 / 0.0000000 / 0.0000000. US/Bay donor prices: No finite positive ratio / No finite positive ratio per 10 QALYs. Gross envelope $103,000; US/Bay/SF resource prices: No finite positive ratio / No finite positive ratio / No finite positive ratio per 10 QALYs.

Uncertainty. Joint scenarios are not confidence bounds. The strong favorable case remains $802,836 per 10 SF QALYs; rapid alternative recovery (2 net days) is $414.19M centrally. Zero allocation/activity/effect keeps all gift cost; independent harm can remain negative at zero activity.

5. Funding and previous grants

Conditional research, not a verified donor recommendation. Additional maternal therapy capacity and effect are not established.

The FY2025 consolidated audit and current public housing contract show existing resources, not a current unfunded therapy tranche. Covered mental-health care and January2026 managed-care transition responsibilities remain baseline.

This review does not establish a verified marginal funding offer or a complete history of grants.

Donate

Opens the organization’s giving page. A general donation may not fund the specific activity modeled here; confirm allocation with the recipient.

6. Sources

  1. HPP giving and entity disclosure. Homeless Prenatal Program. Official EIN 94-3146280; unrestricted giving route. Provider disclosure, not fresh IRS certification.. Published: Undated current page; retrieved: September 8, 2026.
  2. Mental Health and Parenting Support. Homeless Prenatal Program. Current bilingual psychotherapy description; no measured maternal course outcomes. Dynamic zero counters are not output observations.. Published: Undated current page; retrieved: September 8, 2026.
  3. Wellness Center. Homeless Prenatal Program. Maternal service context; prenatal classes and support are not causal healthy births.. Published: Undated current page; retrieved: September 8, 2026.
  4. FY2025 consolidated audited statements. HPP; MUN CPAs. Official financial index-linked PDF; primary tables pp.3–7 and note 7 read. Consolidated accounts, not a donor marginal budget.. Published: December 19, 2025; retrieved: September 8, 2026.
  5. MOMCare randomized perinatal depression treatment trial. Grote et al.; Depression and Anxiety. 168 randomized Medicaid participants; multi-component care versus intensive maternity support. HPP fidelity and population transfer unverified.. Published: 2015; retrieved: September 8, 2026.
  6. Incremental Benefit-Cost of MOMCare. Grote et al.; Psychiatric Services. Primary publisher indexed results/table and PubMed abstract inspected; direct full-page retrieval failed. 68 added depression-free days in PTSD subgroup; no corresponding significant benefit established without PTSD. Not QALYs or SF marginal prices.. Published: 2017; retrieved: September 8, 2026.
  7. MOMCare economic study primary abstract. Grote et al.; PubMed. Primary abstract corroborates 68 days and $1,312 incremental depression-care costs; historical 2013-dollar source not used as a current HPP quote.. Published: 2017; retrieved: September 8, 2026.
  8. HPP Safer Families Plan parenting TAY rapid rehousing budget. SF HSH. Primary 30-page packet; pp.20–25 list 2025–2031 term and therapist salary funding. Existing housing/therapy baseline, not maternal trial delivery or an unfunded queue.. Published: Budget July 1, 2025; retrieved: September 8, 2026.
  9. FY2025–26 first-quarter Chapter21B report. SF HSH. Primary indexed report names current agreement 1000035557, term July2025–June2031 and $6,131,147 ceiling. Not annual paid expenditure.. Published: FY2025–26 Q1; retrieved: September 8, 2026.
  10. Maternal and Perinatal Health Care Services. California DHCS. Medi-Cal behavioral-health benefits are baseline, not evidence every person receives timely treatment.. Published: Current page; retrieved: September 8, 2026.
  11. Population Health Management: pregnancy/postpartum transition care. California DHCS. Managed care plans have pregnancy/postpartum transition responsibilities through 12 months; HPP reimbursement and actual local access are unverified.. Published: January 2026 update described on current page; retrieved: September 8, 2026.

Annual expenses: years and sources

Average annual expenses (three consecutive fiscal years): $20,637,505. Organization size is separate from the modeled cost-effectiveness of a donation.

Homeless Prenatal Program Inc

IRS Form 990 whole-entity total expenses, Part I line 18; fiscal years ending June 30

Duplicate FY2025 filings agree on current and prior-year expenses. FY2023 from prior-year column of FY2024 return.